<DOC>
	<DOCNO>NCT00262769</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know whether gemcitabine effective without cisplatin treat cholangiocarcinoma biliary tract tumor . PURPOSE : This randomized phase III trial study gemcitabine cisplatin see well work compare gemcitabine alone treat patient unresectable locally advanced metastatic cholangiocarcinoma biliary tract tumor .</brief_summary>
	<brief_title>Gemcitabine With Without Cisplatin Treating Patients With Unresectable Locally Advanced Metastatic Cholangiocarcinoma Other Biliary Tract Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient unresectable locally advanced metastatic cholangiocarcinoma biliary tract tumor treat gemcitabine hydrochloride v without cisplatin . Secondary - Compare progression-free survival patient treat regimen . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , primary site disease ( gallbladder v bile ducts vs ampulla ) , prior therapy ( photodynamic therapy [ PDT ] v non-PDT therapy v none ) , ECOG performance status ( 0 vs 1 v 2 ) , disease status ( locally advance vs metastatic ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine hydrochloride IV 30 minute cisplatin IV 1½ hour day 1 8 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Quality life assess baseline , 12 week , finish treatment . After completion study treatment , patient follow periodically least 3 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 400 patient accrue study .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm biliary tract , gallbladder , ampullary carcinoma Intra extrahepatic disease allow Unresectable locally advance , recurrent , metastatic disease No brain metastasis PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL ( transfusion allow ) WBC ≥ 3,000/mm^3 Hepatic AST ALT ≤ 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Bilirubin ≤ 1.5 time ULN Alkaline phosphatase ≤ 3 time ULN ( 5 time ULN liver metastasis present ) Adequate biliary drainage No unresolved biliary tract obstruction Renal Creatinine &lt; 1.5 time ULN Urea &lt; 1.5 time ULN Glomerular filtration rate ( GFR ) ≥ 45 mL/min If GFR &lt; 60 mL/min , isotope EDTA confirmation adequate renal function require Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No active , uncontrolled infection No severe uncontrolled systemic disease No malignancy within past 5 year except nonmetastatic basal cell squamous cell skin cancer carcinoma situ cervix treat conebiopsy resection No psychiatric disorder would preclude give informed consent PRIOR CONCURRENT THERAPY : Chemotherapy At least 6 month since prior adjuvant chemotherapy No prior gemcitabine hydrochloride No prior cisplatin No prior systemic chemotherapy locally advance metastatic disease except lowdose radiosensitizing chemotherapy conjunction radiotherapy Radiotherapy Prior radiotherapy localize disease allow provide clear evidence disease progression afterwards Surgery Prior curative surgery allow provide evidence nonresectable disease relapse require systemic chemotherapy Other Recovered prior therapy Prior photodynamic therapy ( PDT ) allow provide give localized disease ( evidence metastatic disease ) result subsequent disease progression completion therapy OR relieve biliary obstruction presence metastatic disease PDT must complete ≥ 4 week ago At least 4 week since prior investigational agent No concurrent , curative anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>metastatic extrahepatic bile duct cancer</keyword>
	<keyword>metastatic gallbladder cancer</keyword>
</DOC>